이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 난소암 성인 여성에서 REGN5668을 Cemiplimab 또는 REGN4018과 병용 투여한 연구

2026년 9월 20일 업데이트: Regeneron Pharmaceuticals

세미플리맙 또는 REGN4018(MUC16xCD3)과 병용 투여된 REGN5668(MUC16xCD28, 공동자극 이중특이성)의 1/2상 연구

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

612

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, 미국, 92618
        • 모병
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange, California, 미국, 92868
        • 모병
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa, Florida, 미국, 33612
        • 완전한
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • 모병
        • Karmanos Cancer Institute
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle, Washington, 미국, 98109
        • 모병
        • Seattle Cancer Care Alliance at South Lake Union - G3630
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, 벨기에, 3000
        • 모병
        • Universitair Ziekenhuis Leuven
      • São Paulo, 브라질, 01509-010
        • 모병
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90619-900
        • 모병
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos, São Paulo, 브라질, 14784-400
        • 모병
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba, São Paulo, 브라질, 18065-100
        • 모병
        • Unimed Sorocaba
      • Girona, 스페인, 17007
        • 모병
        • Institut Catala dOncologia Girona
      • Madrid, 스페인, 28040
        • 모병
        • Hospital Universitario Fundacion Jimenez
      • Madrid, 스페인, 28040
        • 모병
        • Ciudad Universitaria
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela, A Coruna, 스페인, 15706
        • 모병
        • Hospital Clinico Universitario Santiago de Compostela
      • Villejuif, 프랑스, 94805
        • 모병
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite, Auvergne-Rhône, 프랑스, 69310
        • 모병
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon, Bourgogne-Franche-Comté, 프랑스, 21000
        • 모병
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux, New Aquitaine, 프랑스, 33076
        • 모병
        • Institut Bergonie
    • Normandy
      • Caen, Normandy, 프랑스, 14076
        • 모병
        • Centre Francois Baclesse (CFB)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

다른 이름들:
  • ubletamig

Administer per the protocol

다른 이름들:
  • REGN2810
  • 리브타요®

Administer per the protocol

실험적: Module 2

REGN5668 and ubamatamab

Administer per the protocol

다른 이름들:
  • ubletamig

Administer per the protocol

다른 이름들:
  • REGN4018

Administer per the protocol

다른 이름들:
  • 케브자라®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of Dose Limiting Toxicities (DLT)
기간: 42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
기간: 21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
기간: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
기간: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
기간: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
기간: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
기간: Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
기간: Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
ORR based on RECIST 1.1
기간: Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
기간: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 12월 8일

기본 완료 (추정된)

2028년 11월 8일

연구 완료 (추정된)

2028년 11월 8일

연구 등록 날짜

최초 제출

2020년 10월 9일

QC 기준을 충족하는 최초 제출

2020년 10월 9일

처음 게시됨 (실제)

2020년 10월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 20일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • R5668-ONC-1938
  • 2022-501904-83-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 공유 기간

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 공유 액세스 기준

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .